Pharmacokinetics of intravenous and oral losartan in patients with heart failure

Journal of Clinical Pharmacology

Volumn 38, Issue 6, 1998, Pages 525-532

  Lo, Man Wai ^a   Toh, Jenny ^a   Emmert, Scott E ^a   Ritter, Michael A ^a   Furtek, Christine I ^a   Lu, Hannah ^a   Colucci, Wilson S ^b   Uretsky, Barry F ^c   Rucinska, Ewa ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIGOXIN; FUROSEMIDE; LOSARTAN; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HEART FAILURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PLASMA CLEARANCE; RANDOMIZED CONTROLLED TRIAL;

EID: 0031750844     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb05790.x     Document Type: Article

References (14)

1. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS: A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995;25:1345-1350.
2. Tsunoda K, Abe K, Hagino T, Omata K, Misawa S, Imai Y, Yoshinaga K: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993;6:28-32.
3. Weber MA, Byyny RL, Pratt H, Faison EP, Snavely DB, Goldberg AI, Nelson EB: Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med 1995;155:405-411.
4. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995;75:793-795.
5. Parmley WW: Pathophysiology and current therapy of congestive heart failure. J Am Coll Cardiol 1989;13:771-785.
6. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, et al: Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995;91:691-697.
7. Sweet CS, Rucinska EJ: Losartan in heart failure: preclinical experiences and initial clinical outcomes. Eur Heart J 1994; 15(Suppl D):139-144.
8. Shammas FV, Dickstein K: Clinical Pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet 1988;15:94-113.
9. Johnston D, Duffin D: Drug-patient interactions and their relevance in the treatment of heart failure. Am J Cardiol 1992;70: 109C-112C.
10. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
11. Furtek CI, Lo MW: Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography. J Chromatogr Biomed Appl 1992;573:295-301.
12. Lam FC, Hung CR, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74:229-231.
13. Perrier D, Mayersohn M: Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 1982;71:372-373.
14. Gibaldi M, Perrier D (eds.): Pharmacokinetics. Drugs and the Pharmaceutical Sciences, Volume 15, Second edition. New York: Marcel Dekker, 1982.